Latest News

BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer’s drug


Biogen’s new Alzheimer’s drug aduhelm saw limited pickup in its first few months on the market.

Cathie Wood’s Ark Files for New Fund

Previous article

A Meta-morphosis of sentiment that may turn again: Morning Brief

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News